drugset / Trial / NCT06313957
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
42 enrolled
Peking University Cancer Hospital & Institute
Beijing Boren Hospital · collabHenan Cancer Hospital · collabNanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2024-03-14
- Primary completion
- 2026-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-20SP | Unknown | — | Other |